Cargando…

Clinical outcomes associated with kidney function changes in anticoagulated atrial fibrillation patients: An ancillary analysis from the BOREALIS trial

BACKGROUND: Patients with atrial fibrillation (AF) and chronic kidney disease represent a high‐risk group for thromboembolism and bleeding. AIMS: To explore the relationship between kidney function changes and outcomes of stroke/systemic embolism (SE), major bleeding and all‐cause death in anticoagu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Ying, Shantsila, Alena, Lip, Gregory Y. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132193/ https://www.ncbi.nlm.nih.gov/pubmed/32256875 http://dx.doi.org/10.1002/joa3.12306

Ejemplares similares

Differences in outcomes between oral anticoagulation “new starters” and “switchers” in patients with nonvalvular atrial fibrillation: A pooled analysis of the AMADEUS and BOREALIS trials
por: Bai, Ying, et al.
Publicado: (2019)

Suboptimal oral anticoagulant treatment among Chinese non-valvular atrial fibrillation patients: the Nanchang Atrial Fibrillation Project
por: Xiong, Qinmei, et al.
Publicado: (2016)

Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes
por: Vitolo, Marco, et al.
Publicado: (2021)

Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review
por: Deng, Hai, et al.
Publicado: (2017)

Prognostic implication of monocytes in atrial fibrillation: The West Birmingham Atrial Fibrillation Project
por: Shahid, Farhan, et al.
Publicado: (2018)

Emerging Tools for Stroke Prevention in Atrial Fibrillation
por: Voukalis, Christos, et al.
Publicado: (2016)

Role of Monocytes in Heart Failure and Atrial Fibrillation
por: Shahid, Farhan, et al.
Publicado: (2018)

Contemporary management of atrial fibrillation in primary and secondary care in the UK: the prospective long-term AF-GEN-UK Registry
por: Shantsila, Alena, et al.
Publicado: (2022)

Multiple biomarkers and arrhythmia outcome following catheter ablation of atrial fibrillation: The Guangzhou Atrial Fibrillation Project
por: Deng, Hai, et al.
Publicado: (2018)

Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial
por: Proietti, Marco, et al.
Publicado: (2020)

Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation
por: Lau, Yee Cheng, et al.
Publicado: (2016)

Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention
por: Shahid, Farhan, et al.
Publicado: (2016)

Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries
por: Ogawa, Hisashi, et al.
Publicado: (2017)

Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials
por: Proietti, Marco, et al.
Publicado: (2016)

Prediction of very late arrhythmia recurrence after radiofrequency catheter ablation of atrial fibrillation: The MB-LATER clinical score
por: Mujović, Nebojša, et al.
Publicado: (2017)

Educational Intervention Improves Anticoagulation Control in Atrial Fibrillation Patients: The TREAT Randomised Trial
por: Clarkesmith, Danielle E., et al.
Publicado: (2013)

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
por: Shantsila, Eduard, et al.
Publicado: (2020)

Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer
por: Ording, Anne Gulbech, et al.
Publicado: (2022)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function
por: Pham, Phuong, et al.
Publicado: (2020)

Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry
por: Liang, Hai-Feng, et al.
Publicado: (2019)

A U-shaped relationship of body mass index on atrial fibrillation recurrence post ablation: A report from the Guangzhou atrial fibrillation ablation registry
por: Deng, Hai, et al.
Publicado: (2018)

Dynamic changes of monocytes subsets predict major adverse cardiovascular events and left ventricular function after STEMI
por: Boidin, Maxime, et al.
Publicado: (2023)

Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
por: Rhee, Tae-Min, et al.
Publicado: (2022)

TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT)
por: Smith, Danielle E, et al.
Publicado: (2010)

Patients' Perceptions of Atrial Fibrillation, Stroke Risk, and Oral Anticoagulation Treatment: An International Survey
por: Lane, Deirdre A., et al.
Publicado: (2018)

Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world
por: Kozieł, Monika, et al.
Publicado: (2021)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Outcomes associated with sodium glucose co-transporter 2 inhibitors in anticoagulated atrial fibrillation patients
por: Fawzy, A M, et al.
Publicado: (2023)

IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial
por: Shantsila, Eduard, et al.
Publicado: (2016)

Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation
por: Yu, Hee Tae, et al.
Publicado: (2020)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis
por: Lane, Deirdre A., et al.
Publicado: (2018)

Integrated Care for Atrial Fibrillation Using the ABC Pathway in the Prospective APHRS-AF Registry
por: Bucci, Tommaso, et al.
Publicado: (2023)

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
por: Roldán, Vanessa, et al.
Publicado: (2022)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS
por: Ding, Wern Yew, et al.
Publicado: (2021)

Relationship between Renal Function, Fibrin Clot Properties and Lipoproteins in Anticoagulated Patients with Atrial Fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Clinical implications of different types of dementia in patients with atrial fibrillation: Insights from a global federated health network analysis
por: Proietti, Riccardo, et al.
Publicado: (2023)

Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants
por: Ording, Anne Gulbech, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ruplqdhnih9ve8ii8uk3embarg